INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Grant or awardVerified data

Woods Keith reported NGNE

Director · Neurogene Inc. · Neurogene Inc. — Non-Qualified Stock Option (right to buy)

Side
A
Value
—
Shares
12.1K
Price
—
Executed
Feb 20, 2026
Disclosed
Feb 24, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Feb 20 executedFeb 24, 2026 disclosed

NGNE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NGNE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SC
    Shafer ChristinaChief Commercial Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    120.0K sh
    		May 5, 2026May 7, 2026
    traded May 5, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JJ
    Jordan JulieChief Medical Officer
    NGNENeurogene Inc.
    Open-market sale · 10b5-1 plan
    		SELL$18K
    828 sh
    		Mar 26, 2026Mar 30, 2026
    traded Mar 26, 2026
    		+4dSEC FORM 4

    Evidence

    21
    JJ
    Jordan JulieChief Medical Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    4,900 sh
    		Feb 20, 2026Feb 24, 2026
    traded Feb 20, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JJ
    Jordan JulieChief Medical Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    29.6K sh
    		Feb 20, 2026Feb 24, 2026
    traded Feb 20, 2026
    		+4dSEC FORM 4

    Evidence

    21
    CS
    Cobb StuartChief Scientific Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    16.5K sh
    		Feb 20, 2026Feb 24, 2026
    traded Feb 20, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001996804-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 20, 2026
    Published
    Feb 24, 2026
    Ingested by INSIDER
    Nov 5, 04:15 UTC
    Last re-read
    Nov 5, 04:15 UTC

    Extracted facts

    Filer
    Woods Keith
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Neurogene Inc. — Non-Qualified Stock Option (right to buy)
    Ticker
    NGNE
    Shares
    12.1K
    Price per share
    $0
    Execution date (reported)
    Feb 20, 2026
    Owned after transaction
    12.1K shares
    Days from execution to publication
    4

    What this establishes

    Woods Keith filed this Form 4 reporting a grant or award of NGNE on Feb 20, 2026. It became public on Feb 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Woods Keithcik:0001996804
    Issuer
    Neurogene Inc.cik:0001404644

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.